Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
By How Much Is The Clinical Oncology Next Generation Sequencing Market Expected To Expand Between 2025 And 2029?
The domain of clinical oncology next-generation sequencing has experienced swift expansion lately, projected to escalate from a valuation of $0.51 billion in 2024 up to $0.58 billion by 2025, reflecting a compound annual growth rate of 13.9%; this upward trajectory during the preceding years is attributable to progress in genomic studies, the identification of cancer biomarkers, technological progress, and the securing of regulatory clearances.
Anticipation suggests that the clinical oncology next generation sequencing market will experience swift expansion over the coming years, achieving a valuation of $0.94 billion by 2029, propelled by a compound annual growth rate (CAGR) calculated at 12.7%; this upward trajectory throughout the prediction horizon is fundamentally driven by the increasing prevalence of cancer, advancements in precision medicine approaches, the rise of immuno-oncology applications, and the growing adoption of liquid biopsies, alongside key directional shifts such as the prominence of comprehensive genomic profiling (cgp), the continued focus on immuno-oncology, better understanding of tumor evolution and heterogeneity, and the integration of artificial intelligence and machine learning technologies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp
What Are The Main Drivers Boosting The Clinical Oncology Next Generation Sequencing Industry’s Expansion?
Anticipated expansion in global cancer occurrences is set to fuel the progression of the clinical oncology next-generation sequencing market throughout the predicted timeframe. To illustrate this trend, data from the US government agency, the National Cancer Institute, indicated in May 2024 that the United States currently harbors approximately 18.1 million cancer survivors, a number expected to climb to 22.5 million by the year 2032. Furthermore, projections suggest that by 2040, annual new cancer diagnoses globally might reach 29.9 million, corresponding with an estimated rise to 15.3 million cancer-related fatalities. Consequently, this increasing worldwide rate of cancer incidence is forecasted to stimulate greater needs within the clinical oncology next-generation sequencing marketplace.
What Are The Major Segment Categories Driving The Clinical Oncology Next Generation Sequencing Market Growth?
The clinical oncology next generation sequencingmarket covered in this report is segmented –
1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing
2) By Application: Screening, Companion Diagnostics, Other Diagnostics
3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories
Subsegments:
1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies
2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies
3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies
4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies
5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies
6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies
7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies
What Key Innovation Trends Are Fueling Advancements In The Clinical Oncology Next Generation Sequencing Market?
Leading firms within the field of clinical oncology next-generation sequencing are actively introducing novel offerings, exemplified by the BenchMark ULTRA PLUS system, aiming to bolster their financial gains in this sector. This BenchMark ULTRA PLUS System serves as an important asset for clinical diagnostic facilities, especially those focused on cancer investigation and diagnosis, fostering greater precision and streamlined processing of diagnostic assays, which ultimately enhances patient treatment outcomes. As an illustration, in June of 2022, Roche, a pharmaceutical giant headquartered in Switzerland, released the BenchMark ULTRA PLUS system, representing their most advanced tissue staining apparatus; by furnishing rapid and precise test outcomes, this technology assists medical practitioners in determining appropriate patient treatment paths without delay.
Who Are The Top Performing Companies In The Clinical Oncology Next Generation Sequencing Market In Recent Years?
Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.
Download The Full Report For Exclusive Market Findings:
Which Regional Markets Are Contributing Most To The Clinical Oncology Next Generation Sequencing Industry Expansion?
North America was the largest region in the clinical oncology next-generation sequencing market in 2024. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Clinical Oncology Next Generation Sequencing Market Report:
https://www.thebusinessresearchcompany.com/customise?id=3344&type=smp
Browse Through More Reports Similar to the Global Clinical Oncology Next Generation Sequencing Market 2025, By The Business Research Company
Synthetic Biology Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/synthetic-biology-global-market-report
Molecular Diagnostics Devices And Equipment Global Market Report 2025
Molecular Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model